Literature DB >> 21999734

Interaction of human brain acetylcholinesterase with cyclophosphamide: a molecular modeling and docking study.

Shazi Shakil1, Rosina Khan, Shams Tabrez, Qamre Alam, Nasimudeen R Jabir, Mansour I Sulaiman, Nigel H Greig, Mohammad A Kamal.   

Abstract

This study describes the interaction between human acetylcholinesterase (AChE), a key regulator of central and peripheral cholinergic function, and the widely used nitrogen mustard alkylating agent, cyclophosphamide (CP). Modeling of the AChE sequence (NCBI Accession No: AAI05061.1) was performed using 'Swiss Model Workspace'. The protein-model was submitted to the Protein Model Database and was assigned accession number PM0077393. A plot showing normalized QMEAN scores versus protein size was made to compare the model with a non-redundant set of Protein Data Bank structures, which gave a Z-score QMEAN as -0.58. The predicted local error for the modeled structure was found to be well within tolerable limits. Z-score values for Cβ interaction, all atom interaction, solvation and torsion were found to be -1.10, -0.90, -0.06 and -0.40, respectively. Docking between CP and AChE was performed using 'Autodock4.2'. Apart from other interaction-types, six carbon atoms of CP (C1, C2, C3, C4, C6 and C7) were determined to be involved in hydrophobic interactions with amino acid residues Y121, W233, L323, F331, F335 and Y338 of the 'acyl pocket' within AChE. Five carbon atoms of CP (C2, C4, C5, C6 and C7) were involved in hydrophobic interactions with 3 amino acid residues within the enzyme's 'catalytic site'. In conclusion, hydrophobic interactions play a major role in the appropriate positioning of CP within the 'acyl pocket' as well as 'catalytic site' of AChE to permit suitable orientation and allow docking. This information may aid the design of more potent and versatile AChE-inhibitors as pharmacologic tools and drugs to characterize and treat neurological disorders, and additionally provides a model whose value can be quantitatively assessed by X-ray crystallographic analysis of the AChECP three-dimensional structure.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21999734      PMCID: PMC4978224          DOI: 10.2174/187152711798072365

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  26 in total

1.  Progress in the treatment of myasthenia gravis.

Authors:  Ralf Gold; Reinhard Hohlfeld; Klaus V Toyka
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

2.  Thermodynamic investigation of camel retina acetylcholinesterase inhibition by cyclophosphamide.

Authors:  A A al-Jafari; M A Kamal; A S Alhomida
Journal:  J Enzyme Inhib       Date:  1997-02

Review 3.  Myasthenia gravis: options and timing of immunomodulatory treatment.

Authors:  P J Spring; J M Spies
Journal:  BioDrugs       Date:  2001       Impact factor: 5.807

4.  Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray versus molecular dynamics.

Authors:  Yechun Xu; Jacques-Philippe Colletier; Martin Weik; Hualiang Jiang; John Moult; Israel Silman; Joel L Sussman
Journal:  Biophys J       Date:  2008-05-23       Impact factor: 4.033

Review 5.  Front-line management of diffuse large B cell lymphoma.

Authors:  Fernando Cabanillas
Journal:  Curr Opin Oncol       Date:  2010-11       Impact factor: 3.645

6.  Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.

Authors:  S Genka; J Deutsch; P L Stahle; U H Shetty; V John; C Robinson; S I Rapoport; N H Greig
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 7.  Acetylcholinesterase: 'classical' and 'non-classical' functions and pharmacology.

Authors:  Israel Silman; Joel L Sussman
Journal:  Curr Opin Pharmacol       Date:  2005-06       Impact factor: 5.547

8.  Multiple approaches to analyse the data for rat brain acetylcholinesterase inhibition by cyclophosphamide.

Authors:  Mohammad A Kamal; M Reale; Abdulaziz A Al-Jafari
Journal:  Neurochem Res       Date:  2010-07-21       Impact factor: 3.996

9.  Expression of cholinesterases in human kidney and its variation in renal cell carcinoma types.

Authors:  Encarnación Muñoz-Delgado; María Fernanda Montenegro; Francisco Javier Campoy; María Teresa Moral-Naranjo; Juan Cabezas-Herrera; Gyula Kovacs; Cecilio J Vidal
Journal:  FEBS J       Date:  2010-09-30       Impact factor: 5.542

Review 10.  Cyclophosphamide and cancer: golden anniversary.

Authors:  Ashkan Emadi; Richard J Jones; Robert A Brodsky
Journal:  Nat Rev Clin Oncol       Date:  2009-09-29       Impact factor: 66.675

View more
  4 in total

1.  Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses.

Authors:  Mohammad A Kamal; Shazi Shakil; Muhammad S Nawaz; Qian-Sheng Yu; David Tweedie; Y Tan; Xianqin Qu; Nigel H Greig
Journal:  CNS Neurol Disord Drug Targets       Date:  2017       Impact factor: 4.388

Review 2.  Cholinesterase targeting by polyphenols: A therapeutic approach for the treatment of Alzheimer's disease.

Authors:  Nasimudeen R Jabir; Fayaz Rahman Khan; Shams Tabrez
Journal:  CNS Neurosci Ther       Date:  2018-05-16       Impact factor: 5.243

3.  Structure-Based Scaffold Repurposing toward the Discovery of Novel Cholinesterase Inhibitors.

Authors:  Satish N Dighe; Mangapathiraju Tippana; Suzannah van Akker; Trudi A Collet
Journal:  ACS Omega       Date:  2020-11-24

4.  Protective Effect of Edaravone on Cyclophosphamide Induced Oxidative Stress and Neurotoxicity in Rats.

Authors:  Sanjiv Singh; Abhishek Kumar
Journal:  Curr Drug Saf       Date:  2019
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.